Mark Sabag

Mark Sabag discloses dealings in Teva Pharmaceutical Industries Ltd to SEC (Form 4). Between 14 February 2018 and 17 March 2026, the trades on record add up to 47 filings.

The open-market record consists of 10 sales worth €18.6M, with no purchase. The rest of the record consists of 2 share grants and 35 option exercises. Since January 2026: no purchases and 1 sale on the market.

The record was last updated on 19 March 2026 with an open-market sale (€1.6M) in Teva Pharmaceutical Industries Ltd. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.